duvakitug vs XmAb942

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: TL1A · full Ulcerative Colitis pipeline

duvakitug

Developed by Teva Pharmaceutical Industries and partners

Phase 3 in Ulcerative Colitismonoclonal antibody (IgG1-λ2)
Partial signal

NCT05499130 · Phase 2b · completed

Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2028 · NCT07184996 (registry estimate)

Reported efficacy

Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)

Result source: NCT05499130

XmAb942

Developed by Xencor

Phase 1/2 in Ulcerative Colitismonoclonal antibody (long-acting anti-TL1A, Xtend half-life technology)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT06619990 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointduvakitugXmAb942
Clinical remission (induction)47.8% vs 20.5%+27.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 36.2% vs 20.5% 450 mg · wk 14 · n 47 · Phase 2b · primary NCT05499130
  • 23.9% vs 9.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 29.8% vs 9.1% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
—Not reported
Clinical remission (maintenance)—Trial running · NCT07185009—Not reported
Clinical response (induction)69.6% vs 52.3%+17.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 73.9% vs 50% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 80.9% vs 52.3% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
  • 83% vs 50% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
—Not reported
Endoscopic improvement (induction)—Trial running · NCT07185009—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT07185009—Not reported

Clinical remission (induction)

duvakitug
47.8% vs 20.5%+27.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 36.2% vs 20.5% 450 mg · wk 14 · n 47 · Phase 2b · primary NCT05499130
  • 23.9% vs 9.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 29.8% vs 9.1% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
XmAb942
—Not reported

Clinical remission (maintenance)

duvakitug
—Trial running · NCT07185009
XmAb942
—Not reported

Clinical response (induction)

duvakitug
69.6% vs 52.3%+17.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 73.9% vs 50% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 80.9% vs 52.3% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
  • 83% vs 50% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
XmAb942
—Not reported

Endoscopic improvement (induction)

duvakitug
—Trial running · NCT07185009
XmAb942
—Not reported

Corticosteroid-free remission (maintenance)

duvakitug
—Trial running · NCT07185009
XmAb942
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

XmAb942: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. duvakitug: 4 of 4 rows · XmAb942: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricduvakitug
Dropout rate
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
8.5%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
19.6%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Discontinued due to AEs
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.1%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
8.7%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Serious AEs
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
13%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Most frequent reported AEs
1800 mga
eczema 33.3% (placebo 0%)
influenza 33.3% (placebo 2.2%)
proteinuria 33.3% (placebo 0%)
NCT05499130 · Phase 2b · monotherapy
show 5 more results
1800 mg
abnormal uterine bleeding 14.3% (placebo 0%)
insomnia 14.3% (placebo 0%)
anaemia 0% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
900 mg
nasopharyngitis 6.5% (placebo 6.5%)
headache 2.2% (placebo 2.2%)
vomiting 2.2% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy
900 mg
headache 4.3% (placebo 2.2%)
influenza 4.3% (placebo 2.2%)
anaemia 2.2% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
450 mg
headache 8.7% (placebo 2.2%)
anaemia 6.5% (placebo 2.2%)
nasopharyngitis 4.3% (placebo 6.5%)
NCT05499130 · Phase 2b · monotherapy
450 mg
nasopharyngitis 6.4% (placebo 6.5%)
upper respiratory tract infection 6.4% (placebo 4.3%)
vomiting 6.4% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

duvakitug

Clinical Remission 47.8% (n=46) vs 20.5% (n=44) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 22 Participants as posted
show 3 more results
23.9% (n=46) vs 9.1% (n=44) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 11 Participants as posted
36.2% (n=47) vs 20.5% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 17 Participants as posted
29.8% (n=47) vs 9.1% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 14 Participants as posted
Clinical Response 69.6% (n=46) vs 52.3% (n=44) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 32 Participants as posted
show 3 more results
73.9% (n=46) vs 50% (n=44) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 34 Participants as posted
80.9% (n=47) vs 52.3% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 38 Participants as posted
83% (n=47) vs 50% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 39 Participants as posted
Endoscopic Improvement 50% (n=46) vs 22.7% (n=44) placebo @ 14wk900 mg
event count · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 23 Participants as posted
show 1 more result
44.7% (n=47) vs 22.7% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 21 Participants as posted
Endoscopic Remission 17.4% (n=46) vs 6.8% (n=44) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted
show 1 more result
17% (n=47) vs 6.8% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: duvakitug's landscape · XmAb942's landscape